Alec DeSimone, PhD, currently a postdoctoral researcher at Yale School of Medicine, was the winner of the Best Poster Award at the 2021 International Research Congress, held virtually on June 24-25. The title of his poster “A live-cell drug screening platform for FSHD therapeutics,” co-authored with Drs. Angela Lek and Monkol Lek, describes a cost-effective,… Read More »
2021 Best Poster Award goes to Alec DeSimone
Giorgio Tasca wins 2021 Young Investigator Award
The 2021 FSHD Society Young Investigator Award at the International Research Congress was awarded to Giorgio Tasca, MD PhD, a neurologist at the Fondazione Policlinico Universitario in Rome, Italy. Dr. Tasca received his medical degree (MD) with honors at the Catholic University in Rome, Italy in 2005 and his PhD in Neuroscience at the same… Read More »
ReDUX4 trial result exceeds expectations
By June Kinoshita, Director of Research and Patient Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”—Fulcrum Therapeutics Fulcrum Therapeutics announced today that losmapimod, its experimental therapy for facioscapulohumeral muscular dystrophy, produced statistically significant improvements in function and decreased fatty infiltration of muscle in its ReDUX4 clinical trial…. Read More »
Tell your doctor about the FSHD Masterclass
The FSHD Society is offering its first-ever CME-accredited masterclass on facioscapulohumeral muscular dystrophy (FSHD). This course, which will be held virtually on August 12, is of interest to any physician and allied health professional who sees adult and pediatric neuromuscular patients. They will be able to earn up to 4.25 continuing medical education (CME) credits—a… Read More »
Calling all parents of early-onset FSHD children
The FSHD Society is launching a new chapter for families with early-onset FSHD (also called infantile FSHD). Led by Ally Roets, the chapter will meet virtually to serve people everywhere who have affected family members. Early-onset FSHD is defined by facial muscle weakness before the age of 5 and shoulder/arm weakness by age 10. Children… Read More »